Novelix Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 200695,
    "name": "Novelix Pharma.",
    "stock_name": "Novelix Pharma.",
    "full_name": "Novelix Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/novelix-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "62.85",
    "chg": 2.88,
    "chgp": "4.8%",
    "dir": 1,
    "prev_price": "59.97",
    "mcapval": "111.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 536565,
    "symbol": "",
    "ind_name": "Retailing",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE314I01036",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "5.5 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/novelix-pharma-200695-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-hits-lower-circuit-amid-market-turmoil-3745843",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3745843.png",
        "date": "2025-12-04 09:35:28",
        "description": "Novelix Pharmaceuticals Ltd experienced a sharp decline today, marked by exclusive selling activity and a lower circuit lock at Rs 59.75. The stock’s performance contrasts starkly with the broader market, signalling distress selling and heightened investor caution."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit Lockdown",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3743312",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3743312.png",
        "date": "2025-12-03 09:40:26",
        "description": "Novelix Pharmaceuticals Ltd experienced a severe downturn on 3 Dec 2025, marked by an exclusive presence of sell orders and a lower circuit lock that halted any buying activity. The stock’s performance sharply contrasted with broader market trends, signalling distress selling and heightened investor caution within the retailing sector."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-frenzy-3740947",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_buyers_3740947.png",
        "date": "2025-12-02 09:35:23",
        "description": "Novelix Pharmaceuticals has witnessed extraordinary buying momentum, locking in an upper circuit with exclusively buy orders in the queue. This remarkable demand, coupled with a string of consecutive gains, signals a potential multi-day circuit scenario for the retailing sector stock."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3737831",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_buyers_3737831.png",
        "date": "2025-12-01 09:55:14",
        "description": "Novelix Pharmaceuticals has captured market attention with extraordinary buying interest, registering an upper circuit scenario marked by a complete absence of sellers. This rare market phenomenon signals robust demand and the potential for sustained gains over multiple trading sessions."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-surges-on-unprecedented-buying-interest-hits-upper-circuit-3734961",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovelixPharmace_only_buyers_3734961.png",
        "date": "2025-11-28 09:40:17",
        "description": "Novelix Pharmaceuticals has demonstrated extraordinary buying interest, registering a significant price surge accompanied by an upper circuit scenario with exclusively buy orders in the queue. This remarkable momentum highlights a potential multi-day circuit trend, underscoring robust demand in the retailing sector."
      },
      {
        "title": "Is Novelix Pharma. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novelix-pharma-overvalued-or-undervalued-3734472",
        "imagepath": "",
        "date": "2025-11-28 08:07:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Elevated Pricing</strong></p>\n<p>Novelix Pharma currently trades at a price-to-earnings (PE) ratio exceeding 97, a figure that significantly surpasses typical industry standards and peer averages. This elevated PE ratio suggests that investors are pricing in substantial future growth or are paying a premium for the stock. The price-to-book (P/B) ratio stands at 3.60, which, while not extreme, is above the average for many pharmaceutical companies, indicating that the market values the company’s net assets at a considerable premium.</p>\n<p>Enterprise value multiples further reinforce this view. The EV to EBIT and EV to EBITDA ratios are approximately 70.4 and 68.3 respectively, both markedly higher than those of comparable firms in the sector. Such multiples imply t..."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3732896",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovelixPharmace_only_buyers_3732896.png",
        "date": "2025-11-27 09:40:28",
        "description": "Novelix Pharmaceuticals has witnessed extraordinary buying momentum today, locking in an upper circuit with exclusively buy orders in the queue. This rare market phenomenon highlights intense investor interest and suggests the potential for a sustained multi-day circuit scenario."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest, Eyeing Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3731147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovelixPharmace_only_buyers_3731147.png",
        "date": "2025-11-26 10:30:16",
        "description": "Novelix Pharmaceuticals has witnessed extraordinary buying momentum, registering a sharp price rise today with only buy orders in the queue. This rare market phenomenon signals a potential multi-day upper circuit scenario, reflecting robust investor enthusiasm despite recent volatility."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-intense-selling-pressure-hits-lower-circuit-amid-market-turmoil-3729210",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovelixPharmace_only_sellers_3729210.png",
        "date": "2025-11-25 15:00:19",
        "description": "Novelix Pharmaceuticals has encountered significant selling pressure today, with the stock registering a sharp decline and exhibiting a complete absence of buyers. This distress selling signals a challenging phase for the company’s shares as they continue to underperform relative to the broader market and sector benchmarks."
      }
    ],
    "total": 94,
    "sid": "200695",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/novelix-pharmaceuticals-200695"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "21-Jan-2026",
      "details": "Submission of Certificate Under Reg. 74 (5) of SEBI (DP) Regulations 2018.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "20-Jan-2026",
      "details": "Submission of Intimation of allotment.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On Monday 19Th January 2026",
      "datetime": "19-Jan-2026",
      "details": "Submission of outcome of the board meeting.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has declared <strong>3%</strong> dividend, ex-date: 16 Aug 12",
          "dt": "2012-08-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has announced <strong>10:1</strong> stock split, ex-date: 04 Oct 10",
          "dt": "2010-10-04",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-04 09:35:28

Novelix Pharmaceuticals Ltd experienced a sharp decline today, marked by exclusive selling activity and a lower circuit lock at Rs 59.75. The stock’s performance contrasts starkly with the broader market, signalling distress selling and heightened investor caution.

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit Lockdown

2025-12-03 09:40:26

Novelix Pharmaceuticals Ltd experienced a severe downturn on 3 Dec 2025, marked by an exclusive presence of sell orders and a lower circuit lock that halted any buying activity. The stock’s performance sharply contrasted with broader market trends, signalling distress selling and heightened investor caution within the retailing sector.

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock

2025-12-02 09:35:23

Novelix Pharmaceuticals has witnessed extraordinary buying momentum, locking in an upper circuit with exclusively buy orders in the queue. This remarkable demand, coupled with a string of consecutive gains, signals a potential multi-day circuit scenario for the retailing sector stock.

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum

2025-12-01 09:55:14

Novelix Pharmaceuticals has captured market attention with extraordinary buying interest, registering an upper circuit scenario marked by a complete absence of sellers. This rare market phenomenon signals robust demand and the potential for sustained gains over multiple trading sessions.

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum

2025-11-28 09:40:17

Novelix Pharmaceuticals has demonstrated extraordinary buying interest, registering a significant price surge accompanied by an upper circuit scenario with exclusively buy orders in the queue. This remarkable momentum highlights a potential multi-day circuit trend, underscoring robust demand in the retailing sector.

Is Novelix Pharma. overvalued or undervalued?

2025-11-28 08:07:11

Valuation Metrics Indicate Elevated Pricing Novelix Pharma currently trades at a price-to-earnings (PE) ratio exceeding 97, a figure that significantly surpasses typical industry standards and peer averages. This elevated PE ratio suggests that investors are pricing in substantial future growth or are paying a premium for the stock. The price-to-book (P/B) ratio stands at 3.60, which, while not extreme, is above the average for many pharmaceutical companies, indicating that the market values the company’s net assets at a considerable premium. Enterprise value multiples further reinforce this view. The EV to EBIT and EV to EBITDA ratios are approximately 70.4 and 68.3 respectively, both markedly higher than those of comparable firms in the sector. Such multiples imply t...

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock

2025-11-27 09:40:28

Novelix Pharmaceuticals has witnessed extraordinary buying momentum today, locking in an upper circuit with exclusively buy orders in the queue. This rare market phenomenon highlights intense investor interest and suggests the potential for a sustained multi-day circuit scenario.

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest, Eyeing Multi-Day Upper Circuit

2025-11-26 10:30:16

Novelix Pharmaceuticals has witnessed extraordinary buying momentum, registering a sharp price rise today with only buy orders in the queue. This rare market phenomenon signals a potential multi-day upper circuit scenario, reflecting robust investor enthusiasm despite recent volatility.

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-25 15:00:19

Novelix Pharmaceuticals has encountered significant selling pressure today, with the stock registering a sharp decline and exhibiting a complete absence of buyers. This distress selling signals a challenging phase for the company’s shares as they continue to underperform relative to the broader market and sector benchmarks.

View All News